Anand Giddabasappa
Anand Giddabasappa has a total of 181 co-authors. Here are the top co-authors by number of shared publications:
- Ziyue Karen Jiang
AI Laboratory Zhejiang University Shanghai
86 shared publications - Sripad Ram
Pfizer, Inc
84 shared publications - Lisa K. Manzuk
Comparative Medicine, Pfizer Worldwide Research, Development and Medical, San Diego, California
83 shared publications - Kavon Noorbehesht
Animal Models and Imaging, Comparative Medicine-Drug Safety R&D, Pfizer Inc., San Diego, California
60 shared publications - Timothy Affolter
Global Pathology, Comparative Medicine-Drug Safety R&D, Pfizer Inc., San Diego, California
60 shared publications - Catherine Lee
Zentalis Pharmaceuticals, Inc., 10275 Science Center Drive, Suite 200, San Diego, CA, USA
54 shared publications
Latest Publications
- Open Access
- 27 March 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1637129
Rational modulation of immune mechanisms synergizes the anti-tumor effects of targeted radiation therapy in pre-clinical models
Immunotherapy has revolutionized cancer treatment, offering new hope for many patients. However, while some individuals show remarkable responses, the overall success rate remains limited. This has spurred interest in combination therapies, particularly with established treatments like radiation therapy (RT), to improve outcomes. RT is a cornerstone of cancer therapy and known to influence the immune landscape, yet a systematic characterization of its effects on tumor-infiltrating leukocytes (TILs) and a rationale-based therapy is still lacking. In this study, we employed a diverse set of pre-clinical syngeneic murine tumor models with varying immune profiles to investigate the immunological impact of tumor targeted RT. We observed that immunologically ‘hot’ tumors showed stronger tumor growth inhibition (TGI) after RT compared to ‘cold’ tumors. Additionally, RT induced both pro- and anti-inflammatory shifts within the tumor immune microenvironment. Importantly, RT led to an intra-tumoral increase in proliferating CD8 + T cells, while the population of proliferating macrophages was notably reduced. To identify immune-modulatory pathways that shape the response to RT across different tumor immune contexts, we tested RT in HPK1 (Hematopoietic Progenitor Kinase 1) and STING (Stimulator of Interferon Genes) deficient mice. These experiments revealed that STING deficiency compromises TGI in tumors with a high baseline population of myeloid cells expressing an interferon response signature. Moreover, we identified a synergistic effect on survival in tumor-bearing mice when combining HPK1 deficiency with RT. Thus, RT promotes expansion of cytotoxic T cells while limiting macrophage proliferation, with therapeutic outcomes strongly influenced by STING and HPK1 pathways. Collectively, these results highlight the complex interplay between RT, tumor immune microenvironment and response to therapy, offering potential avenues for novel therapeutic combinations.
- 27 March 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1637129
Open AccessRational modulation of immune mechanisms synergizes the anti-tumor effects of targeted radiation therapy in pre-clinical models
Immunotherapy has revolutionized cancer treatment, offering new hope for many patients. However, while some individuals show remarkable responses, the overall success rate remains limited. This has spurred interest in combination therapies, particularly with established treatments like radiation therapy (RT), to improve outcomes. RT is a cornerstone of cancer therapy and known to influence the immune landscape, yet a systematic characterization of its effects on tumor-infiltrating leukocytes (TILs) and a rationale-based therapy is still lacking. In this study, we employed a diverse set of pre-clinical syngeneic murine tumor models with varying immune profiles to investigate the immunological impact of tumor targeted RT. We observed that immunologically ‘hot’ tumors showed stronger tumor growth inhibition (TGI) after RT compared to ‘cold’ tumors. Additionally, RT induced both pro- and anti-inflammatory shifts within the tumor immune microenvironment. Importantly, RT led to an intra-tumoral increase in proliferating CD8 + T cells, while the population of proliferating macrophages was notably reduced. To identify immune-modulatory pathways that shape the response to RT across different tumor immune contexts, we tested RT in HPK1 (Hematopoietic Progenitor Kinase 1) and STING (Stimulator of Interferon Genes) deficient mice. These experiments revealed that STING deficiency compromises TGI in tumors with a high baseline population of myeloid cells expressing an interferon response signature. Moreover, we identified a synergistic effect on survival in tumor-bearing mice when combining HPK1 deficiency with RT. Thus, RT promotes expansion of cytotoxic T cells while limiting macrophage proliferation, with therapeutic outcomes strongly influenced by STING and HPK1 pathways. Collectively, these results highlight the complex interplay between RT, tumor immune microenvironment and response to therapy, offering potential avenues for novel therapeutic combinations.
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Efficacy and Imaging-Enabled Pharmacodynamic Profiling of KRAS G12C Inhibitors in Xenograft and Genetically Engineered Mouse Models of Cancer
Compound A modulates glucose metabolism and pERK signaling in MiaPaCa2 tumors after 3 days of treatment in the PET imaging cohort of animals
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Efficacy and Imaging-Enabled Pharmacodynamic Profiling of KRAS G12C Inhibitors in Xenograft and Genetically Engineered Mouse Models of Cancer
Compound A modulates glucose metabolism and pERK signaling in MiaPaCa2 tumors after 3 days of treatment in the PET imaging cohort of animals
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Efficacy and Imaging-Enabled Pharmacodynamic Profiling of KRAS G12C Inhibitors in Xenograft and Genetically Engineered Mouse Models of Cancer
Tolerability and individual MiaPaCa2 tumor growth data from animals treated with two weeks of Compound A
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Efficacy and Imaging-Enabled Pharmacodynamic Profiling of KRAS G12C Inhibitors in Xenograft and Genetically Engineered Mouse Models of Cancer
Tolerability and individual MiaPaCa2 tumor growth data from animals treated with two weeks of Compound A
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from Efficacy and Imaging-Enabled Pharmacodynamic Profiling of KRAS G12C Inhibitors in Xenograft and Genetically Engineered Mouse Models of Cancer
Individual MLAST curves and biomarker staining from G12C KP animals treated with vehicle, Compound A, and sotorasib
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from Efficacy and Imaging-Enabled Pharmacodynamic Profiling of KRAS G12C Inhibitors in Xenograft and Genetically Engineered Mouse Models of Cancer
Individual MLAST curves and biomarker staining from G12C KP animals treated with vehicle, Compound A, and sotorasib
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Efficacy and Imaging-Enabled Pharmacodynamic Profiling of KRAS G12C Inhibitors in Xenograft and Genetically Engineered Mouse Models of Cancer
Baseline and post-treatment PET/CT images of individual KrasLSL-G12C/wtp53fl/fl animals treated with vehicle or Compound A
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from Efficacy and Imaging-Enabled Pharmacodynamic Profiling of KRAS G12C Inhibitors in Xenograft and Genetically Engineered Mouse Models of Cancer
Baseline and post-treatment PET/CT images of individual KrasLSL-G12C/wtp53fl/fl animals treated with vehicle or Compound A
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Efficacy and Imaging-Enabled Pharmacodynamic Profiling of KRAS G12C Inhibitors in Xenograft and Genetically Engineered Mouse Models of Cancer
Comparative activity data for Compound A and sotorasib
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Efficacy and Imaging-Enabled Pharmacodynamic Profiling of KRAS G12C Inhibitors in Xenograft and Genetically Engineered Mouse Models of Cancer
Comparative activity data for Compound A and sotorasib
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S7 from Efficacy and Imaging-Enabled Pharmacodynamic Profiling of KRAS G12C Inhibitors in Xenograft and Genetically Engineered Mouse Models of Cancer
G12C KP model survival data from long-term treatment with Compound A
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S7 from Efficacy and Imaging-Enabled Pharmacodynamic Profiling of KRAS G12C Inhibitors in Xenograft and Genetically Engineered Mouse Models of Cancer
G12C KP model survival data from long-term treatment with Compound A
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Efficacy and Imaging-Enabled Pharmacodynamic Profiling of KRAS G12C Inhibitors in Xenograft and Genetically Engineered Mouse Models of Cancer
Summarized G12C KP survival data from long-term treatment with Compound A
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Efficacy and Imaging-Enabled Pharmacodynamic Profiling of KRAS G12C Inhibitors in Xenograft and Genetically Engineered Mouse Models of Cancer
Summarized G12C KP survival data from long-term treatment with Compound A
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Efficacy and Imaging-Enabled Pharmacodynamic Profiling of KRAS G12C Inhibitors in Xenograft and Genetically Engineered Mouse Models of Cancer
Baseline differences in tumor progression and histopathology of G12D versus G12C KP GEM models
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Efficacy and Imaging-Enabled Pharmacodynamic Profiling of KRAS G12C Inhibitors in Xenograft and Genetically Engineered Mouse Models of Cancer
Baseline differences in tumor progression and histopathology of G12D versus G12C KP GEM models